Search

Evaluations of vocational education and training (VET) programs play a key role in informing training policy in Australia and elsewhere. Increasingly, such evaluations use observational data from surveys or administrative collections to assess the effectiveness of VET programs and interventions. The difficulty associated with using observational data is that they are inherently prone to selection bias, which results from individuals self-selecting into a given VET program based on differences in background characteristics or other external factors. The effects of the VET program on outcomes of interest are thus confounded with the effects of pre-existing systematic differences between program participants and non-participants. Propensity score matching (PSM) can mitigate selection bias in evaluation studies with observational data by statistically balancing program participants and non-participants post hoc on observed background characteristics. This article seeks to offer a general introduction to PSM and to provide interested VET researchers with an initial stepping stone for using the method in their own work. (Contains 2 figures, 1 table and 2 footnotes.)

Background: Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine development.Methods: A phase 1, placebo-controlled, dose-escalation trial was conducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with or without adjuvant. Safety and immunogenicity were assessed through 1-year postdosing.Results: All EBOV GP vaccine formulations were well tolerated. Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day 35 representing 498- to 754-fold increases from baseline; no evidence of an antigen dose response was observed. Serum EBOV-neutralizing and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year.Conclusions: Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted. [ABSTRACT FROM AUTHOR]

The United States faces a significant problem with access to oral health care, particularly for children. More than 50 countries have developed an alternative dental provider, a dental therapist, practicing in public, school-based programs, to address children's access to care. This delivery model has been demonstrated to improve access to care and oral health outcomes while providing quality care economically. We summarize elements of a recent major review of the global literature on the use of dental therapists, "A Review of the Global Literature on Dental Therapists: In the Context of the Movement to Add Dental Therapists to the Oral Health Workforce in the United States." We contrast the success of a school-based model of caring for children by dental therapists with that of the US model of dentists providing care for children in private practices. [ABSTRACT FROM AUTHOR]